Biosimilar Competition and Patient Out-of-Pocket Costs
By Danélia Botes
May 6, 2024
Introduction
The American healthcare landscape is witnessing a significant shift with the introduction of biosimilars, designed to create market competition and reduce the financial burden of biologic medications. In 2021, patients and payers in the US spent over $500 billion on prescription drugs, with biologics representing a substantial portion of these costs. This article examines the impact of biosimilar competition on out-of-pocket (OOP) costs for patients using biologics including filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab.
Understanding Biosimilars
Biosimilars are analogous to generic drugs but for complex biologic medications. The rationale for their introduction is to provide a cost-effective alternative to expensive brand-name biologics, once patent protections expire. With prices typically 15% to 35% lower, biosimilars are poised to deliver significant savings to the healthcare system. In January 2021, there was just one biosimilar available for epoetin alfa, whereas the other six biologics had a minimum of two biosimilars, with trastuzumab having the highest number of five.
The Cost Conundrum
Infliximab accounted for 31% of patient-years, making it the most often utilised biologic. Conversely, epoetin alfa constituted a mere 3% of patient-years, rendering it the least commonly employed. Despite the potential for reduced costs, the real-world impact on individual patient OOP expenses remains ambiguous. Insurance benefit designs, reimbursement rates, and the timing of deductible fulfilment all contribute to the complexity of assessing biosimilar competition’s direct effect on patient costs.
The Study’s Findings
A recent analysis focused on commercially insured patients using seven clinician-administered biologics with available biosimilars. The results revealed a trend towards increased OOP costs post-biosimilar introduction, challenging the assumption that biosimilars would automatically lead to lower patient expenses.
Variations in Out-of-Pocket Costs
The study highlighted that the influence of biosimilar competition on OOP costs is not uniform across all biologics. While some drugs showed a decrease in OOP expenses following biosimilar entry, others exhibited an increase or no significant change, underscoring the complexity of the issue. Claims for biosimilar infliximab had higher OOP costs than the reference biologic (AOR, 1.22), while claims for bevacizumab showed the opposite tendency (AOR, 0.77).
The Disconnect Between Savings and Patient Costs
Despite biosimilars generating nearly $13 billion in savings, these have not translated into lower OOP costs for patients. The study suggests that while biosimilar competition may reduce overall healthcare spending and potentially lower premiums, these benefits do not directly impact individual patient costs.
Biosimilar Competition and Patient Costs
Previous biosimilar-OOP cost studies were inconsistent. Filgrastim found that biosimilar introduction lowered monthly OOP costs only for high-deductible plans. Infliximab biosimilar trials showed a minor decrease in OOP expenses per claim, but higher annual spending owing to cost-sharing and lack of discounts. Biosimilar users had decreased OOP costs per cycle, according to pegfilgrastim studies. The findings underscore the need for regulatory measures to ensure that biosimilar savings enhance patient affordability and access. Policymakers could consider laws to limit OOP expenses for biosimilars or decouple patient cost-sharing from inflated reimbursement rates.
Conclusion
The introduction of biosimilars represents a promising strategy to contain healthcare costs. However, this article indicates that, thus far, biosimilar competition has not consistently lowered the OOP costs for patients using biologics. It is imperative for policymakers to implement strategies that ensure the economic benefits of biosimilars extend to patients, enhancing affordability and access to essential medications.
🧬 Unlock the potential of AI in genetic diagnosis with AI-MARRVEL! Discover how this innovative system is transforming the diagnosis of Rare disorders, making it faster and more accurate than ever. 🚀 #GeneticDiagnosis #AIMARRVEL #LifeSciences #AIinHealthcare
🔍 Struggling with undiagnosed genetic conditions? AI-MARRVEL offers a new hope for patients and clinicians. Learn more about this cutting-edge technology. #PrecisionMedicine #HealthcareInnovation #ArtificialIntelligence
📈 Embrace the future of healthcare with AI-driven solutions that is cost effective. #DigitalHealth #MedicalAI #HealthTech
Discover the balance between fair drug pricing and pharmacy sustainability in our latest article. 📊💡 How does the Inflation Reduction Act shape the future for pharmacies? Find out more and join the conversation on fair drug pricing strategies. #FairDrugPricing #PharmacySustainability #HealthcareReform #LifeSciencesConsulting
🚀 #HealthcareReform is on the horizon in South Africa! 🇿🇦 President Cyril Ramaphosa has signed the #NHI Bill into law, promising universal health coverage and a more equitable society. As the nation prepares for this landmark change, stay informed on what this means for citizens and the healthcare industry. #UniversalHealthCoverage #SouthAfricanHealthcare 🏥💡
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.